Highly multiplexed CRISPR‐Cas9‐nuclease and Cas9‐nickase vectors for inactivation of hepatitis B virus
Explore this paper's citation graph
Summary
All‐in‐one CRISPR‐Cas9‐nuclease and Cas9‐nickase vectors present a model for simultaneous targeting of multiple HBV domains, potentially contributing to a well‐designed therapeutic approach for curing HBV patients.
- Type
- article
- Published
- 2016-11-01
- Cited by
- 63
- References
- 31
- Access
- Open access
- OpenAlex
- https://openalex.org/W2523441707
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:40448500
Keywords
CRISPR, Cas9, Biology, cccDNA, Genome editing
References
- Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication.
- How specific is CRISPR/Cas9 really?
- Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.
- Application of CRISPR/Cas9 Technology to HBV
- Targeted chromosomal deletions in human cells using zinc finger nucleases.
- Nuclease‐mediated genome editing: At the front‐line of functional genomics technology
- Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification
- Efficient TALEN construction and evaluation methods for human cell and animal applications
- CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering
- The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo
- Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system
- In vivo genome editing using Staphylococcus aureus Cas9
- Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs.
- Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases
- Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
- COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites
- Targeted mutagenesis in the sea urchin embryo using zinc-finger nucleases
- Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
- Production of knockout mice by DNA microinjection of various CRISPR/Cas9 vectors into freeze-thawed fertilized oocytes
- Targeting hepatitis B virus cccDNA using CRISPR/Cas9.
Cited by
- Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
- Impairment of the transition from proliferative stage to prehypertrophic stage in chondrogenic differentiation of human induced pluripotent stem cells harboring the causative mutation of achondroplasia in fibroblast growth factor receptor 3
- Rapid generation of genetic diversity by multiplex CRISPR/Cas9 genome editing in rice
- Novel viral and host targets to cure hepatitis B.
- Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field
- Antiviral Goes Viral: Harnessing CRISPR/Cas9 to Combat Viruses in Humans.
- The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
- CRISPR-Cas orthologues and variants: optimizing the repertoire, specificity and delivery of genome engineering tools
- Suppression of HBV replication by the expression of nickase- and nuclease dead-Cas9
- Genome editing technologies to fight infectious diseases
- The future of multiplexed eukaryotic genome engineering
- [Overexpression of DNA-methyltransferases in persistency of cccDNA pool in chronic hepatitis B].
- Applications of CRISPR-Cas9 Technology in Translational Research on Solid-Tumor Cancers
- Gene Therapy for Chronic HBV—Can We Eliminate cccDNA?
- CRISPR/Cas9 Inhibits Multiple Steps of HIV-1 Infection
- CRISPR/Cas9: the Jedi against the dark empire of diseases
- Application advances and prospects of CRISPR/Cas9 genome editing in nematodes
- Harnessing CRISPR/Cas 9 System for manipulation of DNA virus genome
- Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure
- A Multiplex CRISPR/Cas9 System for Use as an Anti-BmNPV Therapeutic
Related papers
- Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment
- HBsAg kinetics during and after nucleos(t)ide analogues described by mathematical modeling
- 구연 : HBsAg이 소실된 환자의 간조직내 B형 간염 바이러스 염기서열 분석 및 임상적 의의
- An Ideal Hallmark Closest to Complete Cure of Chronic Hepatitis B Patients: High-sensitivity Quantitative HBsAg Loss
- Combination Therapy of Pegylated Interferon alpha 2b (PegIFN) and Adefovir Dipivoxil (ADV) in Chronic Hepatitis B (CH-B) Patients Reduces the Reservoir of Transcriptionally Active cccDNA and Hepatitis B Surface Antigen (HBsAg)
- Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy
- Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA
- Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.
- The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
- Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.